<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04983186</url>
  </required_header>
  <id_info>
    <org_study_id>BC-10031</org_study_id>
    <nct_id>NCT04983186</nct_id>
  </id_info>
  <brief_title>mBrain-21 : a Three-month Study on Context-awareness, Physiological Monitoring, and Machine Learning in Migraine and Cluster Headache</brief_title>
  <acronym>MBRAIN-21</acronym>
  <official_title>mBrain-21 : a Three-month Study on Context-awareness, Physiological Monitoring, and Machine Learning in Migraine and Cluster Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study collects data from migraine and cluster headache patients during a three-month&#xD;
      study. Contextual data (e.g. location or smartphone usage) and physiological variables will&#xD;
      be used to assist machine learning algorithms in making predictions on activity, stress and&#xD;
      sleep in patients with migraine or cluster headache.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Migraine and cluster headache are brain disorders with disabling headache attacks and&#xD;
      assoicated symptoms. Attacks have multiple phases such as the premonitory phase, aura phase,&#xD;
      headache phase and postdromal phase. During those phases, symptoms of homeostatic disturbance&#xD;
      or sensory alterations may occur.&#xD;
&#xD;
      The goal of the study is to observe activity, stress and sleep parameters in relation to&#xD;
      registered headache attacks.&#xD;
&#xD;
      Participation in the mBrain-21 study will last maximum 90 days. Participants are patients&#xD;
      with migraine or cluster heacache recruited within the headache clinic of Ghent University&#xD;
      Hospital. Physiological variables such as heart rate, movement and galvanic skin resonse will&#xD;
      be measured by the Empatica E4 wrist sensor. Patient-specific experiences during headache&#xD;
      attacks and activities of daily life will be registered with a custom-made headache&#xD;
      smartphone applications. Contextual data (e.g. smartphone usage or location) can be&#xD;
      autonomously collected through smartphone applications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy (F1-scores) machine learning algorithms</measure>
    <time_frame>After 90 days</time_frame>
    <description>Machine learning algorithms for stress detection, sleep detection, activity detection and headache attack detection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demographics</measure>
    <time_frame>At the beginning of the study</time_frame>
    <description>Demographic characteristics of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache phenotype characteristics</measure>
    <time_frame>At the beginning of the study</time_frame>
    <description>Headache phenotype characteristics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Migraine Specific Questionnaire v2.1</measure>
    <time_frame>After 90 days</time_frame>
    <description>Migraine Specific Questionnaire v2.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MIDAS Migraine Disability Assessment</measure>
    <time_frame>After 90 days</time_frame>
    <description>MIDAS Migraine Disability Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MOS Short-Form General Health Survey (SF-20)</measure>
    <time_frame>After 90 days</time_frame>
    <description>MOS Short-Form General Health Survey (SF-20)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Sleep Quality index</measure>
    <time_frame>After 90 days</time_frame>
    <description>Pittsburgh Sleep Quality index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MUltilevel Assessment of Interoceptive Awareness v2 (MAIAv2)</measure>
    <time_frame>After 90 days</time_frame>
    <description>MUltilevel Assessment of Interoceptive Awareness v2 (MAIAv2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived Stress Scale (PSS-10)</measure>
    <time_frame>After 90 days</time_frame>
    <description>Perceived Stress Scale (PSS-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Connor Davidson Resilience Scale (CD-RISC 25)</measure>
    <time_frame>After 90 days</time_frame>
    <description>Connor Davidson Resilience Scale (CD-RISC 25)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penn State Worry Questionnaire (PSWQ)</measure>
    <time_frame>After 90 days</time_frame>
    <description>Penn State Worry Questionnaire (PSWQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perseverative Thinking Questionnaire (PTQ)</measure>
    <time_frame>After 90 days</time_frame>
    <description>Perseverative Thinking Questionnaire (PTQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ruminative Response Scale (RRS)</measure>
    <time_frame>After 90 days</time_frame>
    <description>Ruminative Response Scale (RRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basic Needs Scale</measure>
    <time_frame>After 90 days</time_frame>
    <description>Basic Needs Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotion Regulation Scale</measure>
    <time_frame>After 90 days</time_frame>
    <description>Emotion Regulation Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroticism (subscale from BFI)</measure>
    <time_frame>After 90 days</time_frame>
    <description>Neuroticism (subscale from BFI)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Feedback from participants</measure>
    <time_frame>After 90 days</time_frame>
    <description>Feedback from participants on compliance, adherence, usability and user experience of study infrastructure</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Migraine</condition>
  <condition>Cluster Headache</condition>
  <arm_group>
    <arm_group_label>Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants wear the Empatica E4 wearable sensor and use the smartphone applications developed by the research team.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Wearable sensor and smartphone application</intervention_name>
    <description>Empatica E4 wearable sensor and custom-made headache smartphone application</description>
    <arm_group_label>Participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult participants between the age of 18 en 65 years.&#xD;
&#xD;
          -  Diagnosis of migraine without aura (ICHD-3 diagnosis 1.1) or migraine with aura&#xD;
             (ICHD-3 diagnosis 1.2) or chronic migraine (ICHD-3 diagnosis 1.3)&#xD;
&#xD;
          -  Headache crystal clear days on minimum 5 days per month on average.&#xD;
&#xD;
          -  Onset of headache syndrome before the age of 50.&#xD;
&#xD;
          -  Attacks of migraine or cluster headache are clearly distinguishable from other types&#xD;
             of headache disorders if present.&#xD;
&#xD;
          -  Participant complies with protocol to use smartphone applications on his or her own&#xD;
             Android-based smartphone (minimum version 8.0) and to provide access to his or her&#xD;
             smartphone dataplan.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicolas Vandenbussche, M.D.</last_name>
    <phone>093324529</phone>
    <email>nicolas.vandenbussche@ugent.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital, Ghent: Department of Neurology</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Vandenbussche, MD</last_name>
      <phone>09 332 45 29</phone>
      <email>nicolas.vandenbussche@ugent.be</email>
    </contact>
    <contact_backup>
      <last_name>Koen Paemeleire, MD PhD</last_name>
      <phone>09 332 45 29</phone>
      <email>koen.paemeleire@uzgent.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 5, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine</keyword>
  <keyword>Cluster Headache</keyword>
  <keyword>Smartphone application</keyword>
  <keyword>Machine Learning</keyword>
  <keyword>Wearable sensor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Cluster Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

